RE: EDITORIAL COMMENT: RE: DIETHYLSTILBESTEROL REVISITED: ANDROGEN DEPRIVATION, OSTEOPOROSIS AND PROSTATE CANCER

Abstract

No AccessJournal of UrologyCLINICAL UROLOGY: Letters to the Editor1 Nov 2002RE: EDITORIAL COMMENT: RE: DIETHYLSTILBESTEROL REVISITED: ANDROGEN DEPRIVATION, OSTEOPOROSIS AND PROSTATE CANCER W. Reid Pitts W. Reid PittsW. Reid Pitts More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64327-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "RE: EDITORIAL COMMENT: RE: DIETHYLSTILBESTEROL REVISITED: ANDROGEN DEPRIVATION, OSTEOPOROSIS AND PROSTATE CANCER." The Journal of Urology, 168(5), p. 2131 References 1 : The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab2001; 86: 4261. Google Scholar 2 : Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab2002; 87: 599. Google Scholar 3 : Estrogens in the treatment of prostate cancer. J Urol1995; 154: 1991. Link, Google Scholar 4 : The protective effects of estrogen on the cardiovascular system. N Engl J Med1999; 340: 1801. Google Scholar 5 : “Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med1996; 335: 453. Google Scholar 6 : Hormone therapy for prostate cancer: results of Veterans Administration Cooperative Urological Research Group studies. NCI Monogr1988; 7: 165. Google Scholar 7 : Clinical and biological activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med1998; 339: 785. Google Scholar © 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byPitts W (2018) Re: Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate CancerJournal of Urology, VOL. 170, NO. 6, (2392-2393), Online publication date: 1-Dec-2003. (2018) Re: Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate CancerJournal of Urology, VOL. 170, NO. 6, (2392-2394), Online publication date: 1-Dec-2003. (2018) Re: Enhancement of Diethylstilbestrol Induced Cytotoxicity by bcl-2 Antisense Oligodeoxynucleotides and a Glutathione Depletor for Prostate Cancer: Reply by AuthorsJournal of Urology, VOL. 170, NO. 5, (1954-1955), Online publication date: 1-Nov-2003.Pitts W (2018) Re: Enhancement of Diethylstilbestrol Induced Cytotoxicity by bcl-2 Antisense Oligodeoxynucleotides and a Glutathione Depletor for Prostate CancerJournal of Urology, VOL. 170, NO. 5, (1954-1954), Online publication date: 1-Nov-2003. Volume 168Issue 5November 2002Page: 2131 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.MetricsAuthor Information W. Reid Pitts More articles by this author Expand All Advertisement PDF downloadLoading ...